Drugs in MeSH Category Antimalarials

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	DOXYCYCLINE	doxycycline	CAPSULE;ORAL	204446-003	May 28, 2015		DISCN	No	No
Monarch Pharms	PROLOPRIM	trimethoprim	TABLET;ORAL	017943-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Glenmark Speclt	ATOVAQUONE	atovaquone	SUSPENSION;ORAL	209685-001	Nov 21, 2018	AB	RX	No	No
Strides Pharma Intl	DOXYCYCLINE	doxycycline	CAPSULE;ORAL	065055-003	Jul 15, 2005	AB	RX	No	Yes
Padagis Israel	DAPSONE	dapsone	GEL;TOPICAL	212657-001	Nov 1, 2023		DISCN	No	No
Lupin Ltd	ATOVAQUONE	atovaquone	SUSPENSION;ORAL	209105-001	Sep 11, 2018		DISCN	No	No

Antimalarials in NLM MeSH: Market Dynamics and Patent Landscape

Last updated: April 25, 2026

What defines the Antimalarials IP and market landscape in MeSH?

NLM MeSH “Antimalarials” is a therapeutic umbrella that covers medicines used to prevent or treat malaria, including classes used for blood-stage disease, liver-stage disease, and anti-vector or prophylactic regimens when they are represented within the MeSH taxonomy. Commercially, the category is driven by:

• Epidemiology and treatment guidelines (WHO and country formularies)
• Regimen composition (monotherapy vs combination therapy)
• Resistance patterns by species and geography
• Public-sector procurement (majority volume in endemic markets)
• Subsidies, tenders, and donor funding (often determine launch timing and net prices)

From a patent point of view, the category shows a repeatable structure:

• “Core molecule” exclusivity (composition of matter) for originators
• “Regimen” and “use” coverage (method-of-treatment, fixed-dose combinations)
• **Chiral/isomer and salt/hydrate refinements that extend practical exclusivity**
• Pediatric, formulation, and manufacturing-process patents that can prolong effective blocking positions

How is demand shaped across the antimalarial portfolio?

Antimalarial demand splits into two economic engines.

Treatment and outbreak response

• Acute malaria incidence drives volume, especially for rapid diagnostics-linked procurement.
• Repurchase cycles track national guidelines and resistance status.

Prevention and intermittent prophylaxis

• Seasonal malaria chemoprevention (SMC) and intermittent preventive treatment (IPT) programs create predictable bulk demand for a subset of actives.
• Travel prophylaxis matters in non-endemic markets but is typically smaller than public-sector volumes in dollar terms.

Procurement and pricing mechanics that matter for valuation

For most antimalarial products, the “market” is less a consumer sales story and more a procurement and reimbursement story:

• Tender-based purchasing in endemic geographies
• Donor co-financing affecting which regimens get adopted
• Local manufacturing and registration lowering cost after patent expiry

Which antimalarial drug classes dominate revenue and why?

The category typically clusters into:

• Artemisinin-based combination therapies (ACTs) for uncomplicated malaria (major revenue driver where adopted)
• Non-artemisinin partners (piperaquine, lumefantrine, amodiaquine, mefloquine, etc.) that shape patent strategy because multiple actives can be protected simultaneously in combination products
• Single-dose gametocytocides (e.g., primaquine/tafenoquine in policy-dependent use)
• Liver-stage prophylaxis (e.g., atovaquone-proguanil and at times other actives depending on region and guideline)

The patent and market interplay is straightforward: when guidelines require specific combination partners, exclusivity on either component can materially delay generic entry.

What are the main patent-prosecution and lifecycle risks in antimalarials?

Antimalarials face distinct lifecycle risks that investors and R&D planners track:

1. Resistance-driven regimen switching
   • If a partner drug loses efficacy, demand can drop before patent expiry, compressing ROI even with continuing exclusivity.
2. Combination dependency
   • ACTs often require patent coverage for fixed-dose combinations and dosing regimens. If only the partner is protected, generics may still enter using alternative regulatory pathways.
3. CMC and fixed-dose formulation barriers
   • Some manufacturers can launch only after meeting bioequivalence and quality requirements. If the originator holds key formulation process patents, generic launch can be slowed.
4. Geographic “launch lag”
   • Patent barriers can be stronger in certain jurisdictions but weaker in others, producing uneven revenue capture.

How does the NLM MeSH “Antimalarials” taxonomy map to practical patent targets?

From an IP diligence perspective, MeSH antimalarials align to three patent “target boxes” used in freedom-to-operate (FTO) work:

• Composition of matter: active pharmaceutical ingredient (API) patents
• Combination and regimen: fixed-dose combinations, dosing schedules, and method-of-treatment
• Safety/usage improvements: new indications, patient subsets, and dosing modifications

MeSH inclusion does not indicate legal strength; it indicates therapeutic category membership. IP strength comes from patent families in priority jurisdictions and the existence of enforceable method/use claims beyond the API.

What is the likely patent strategy landscape across antimalarial development?

Most modern antimalarial portfolios show a pattern:

• Originators protect the “platform” molecule (e.g., artemisinin derivatives and key partners when they are novel or novel combinations)
• Companies extend via:
  • fixed-dose combinations (to align with guideline dosing)
  • new salt forms
  • improved formulations (tablet dispersibility, pediatric dispersible tablets, stability)
  • method claims around dosing schedules and patient populations

Generic entry usually requires navigating:

• claim scope (especially regimen/use claims)
• enforcement geography
• regulatory equivalence and manufacturing process constraints

Where do patent cliffs tend to occur in antimalarials?

Patent cliffs typically cluster around:

• ACT combination partners when combination regimens become standardized after years of guideline stability
• Liver-stage prophylaxis actives where travel prophylaxis demand is steady but price-sensitive
• Gametocytocides where policy adoption changes slowly but can be abrupt once safety and guideline criteria mature

Because public-sector procurement drives adoption, once generic tender replacement happens, price compression can be fast. The result is that even “long tail” claims (formulation or process) may not preserve top-line revenue if procurement switches.

What does the NLM MeSH content imply for evidence of drug coverage?

MeSH provides a taxonomy for indexing the biomedical literature. It supports:

• retrieval of antimalarial clinical evidence
• tracking of new active substances and combination strategies in the literature

However, MeSH is not a legal dataset and cannot replace a patent register. In antimalarials, where multiple actives may be indexed under a single umbrella category, the practical approach is to pull patent families for each API and each fixed-dose combination.

How should investors and developers interpret the patent landscape by therapeutic subgroup?

ACTs and fixed-dose combinations

• Most commercially relevant products sit behind combination protection strategies.
• Expect overlapping families: API plus combination plus formulation.

Gametocytocides

• Patent landscapes often hinge on dosing, safety (especially related to hemolysis risk in specific populations), and patient selection.

Liver-stage prophylaxis

• Patent portfolios often include dosing schedule claims and formulation improvements, since prophylaxis usage patterns differ from treatment.

What are the key takeaways for market entry and R&D planning in antimalarials?

• Antimalarial demand is guideline and resistance-driven, so revenue protection depends on maintaining regimen relevance, not only patent duration.
• Combination products concentrate IP risk and opportunity: protection on either component or on fixed-dose/regimen claims can block entry.
• Public-sector procurement accelerates price replacement once generics are eligible; practical exclusivity matters as much as legal expiry.
• MeSH “Antimalarials” is a category for evidence indexing. For patent work, you must treat it as a mapping layer to specific actives and combination regimens.

Key Takeaways

• The “Antimalarials” MeSH category is a broad taxonomy; the patent landscape is molecule- and regimen-specific.
• Market dynamics are dominated by public-sector procurement, tender replacement, and guideline-driven regimen selection.
• Patent strategies in antimalarials tend to combine composition of matter with combination/regimen and formulation extensions.
• Investors should discount revenue based on the probability of regimen obsolescence due to resistance and guideline updates, not only on legal term remaining.

---

FAQs

1) How does MeSH “Antimalarials” help for patent landscape work?

It helps identify which therapeutic agents and clinical evidence belong to the antimalarial space, but it does not indicate legal protection scope.

2) Why do fixed-dose combinations matter most for antimalarials?

They align with guideline standard-of-care ACT regimens and often concentrate enforceable claims in combination and dosing instructions, not only the API.

3) What is the biggest commercial risk after a patent filing in antimalarials?

Regimen substitution driven by resistance or guideline changes can reduce demand well before patent expiry.

4) Do formulation and process patents meaningfully delay generics?

They can slow launch through regulatory and manufacturing constraints, but procurement tender behavior often determines how fast price erosion occurs.

5) What determines the timing of generic tender replacement?

Regulatory eligibility, bioequivalence approval, and enforceability/coverage strength of combination and regimen claims across key procurement jurisdictions.

---

References (APA)

[1] U.S. National Library of Medicine. (n.d.). MeSH: Antimalarials. National Library of Medicine. https://meshb.nlm.nih.gov/